FDA publishes Guideline Draft on the Registration of Production Sites
![Combination Products](files/eca/userImages/training.img/Z-ECA-Combination-Products-2025.jpg)
Recommendation
11/12 February 2025
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
In our News from 11 September 2013, we reported about FDA's initiative to identify production sites according to a uniform system. The identification should be enabled thanks to a D-U-N-S- (Data Universal Numbering System) number (composed of 9 figures) allocated by the company Dun & Bradstreet.
The topic seems to be crucial for the FDA as it has now released the draft of a "Guidance for Industry" entitled: "Specification of the Unique Facility Identifier (UFI) System for Drug Establishment Registration". The draft comprises 5 pages including the title page. The actual content (introduction, background, and description of the UFI system) is laid down in one and a half pages. In the end, the only statement of the FDA is that the DUNS number is suitable to the identification of sites. If an alternative identifier shall be used, the FDA should be contacted.
The draft was published on 4 September 2013 and can be commented on within 60 days.
The document can be found here.
Related GMP News
11.12.2024Risk Analysis in Case of Insufficient Process Validation
11.12.2024Cloud Computing: Validation documents for a SaaS application
04.12.2024Cloud Computing: What happens if the CSP does not allow audits?
27.11.2024Cloud Computing: Are (GMP) Supervisory Authorities allowed to inspect CSP?
20.11.2024Cloud Computing - Content of a SLA/Contract with a XaaS Provider
23.10.2024FDA criticises the Use of pharmaceutical Facilities for industrial Products